Next, we measured IL-19 levels in patients with psoriasis in a phase 2 trial (investigating the JAK1/2 inhibitor baricitinib) at baseline and after 12 weeks of treatment with placebo or various doses of baricitinib and compared IL-19 levels with PASI scores (Fig. 3a). This evidence concerns the gene IL19 and psoriasis.